SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E. Trinka, B. J. Steinhoff, M. Nikanorova, M. J. Brodie, Perampanel for focal epilepsy: insights from early clinical experience, Acta Neurologica Scandinavica, 2016, 133, 3
  2. 2
    Adam Strzelczyk, Laurent M Willems, Sophia Willig, Felix Rosenow, Sebastian Bauer, Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus, Expert Review of Clinical Pharmacology, 2015, 8, 6, 733

    CrossRef

  3. 3
    James E. Frampton, Perampanel: A Review in Drug-Resistant Epilepsy, Drugs, 2015, 75, 14, 1657

    CrossRef

  4. 4
    Caterina Palleria, Antonietta Coppola, Rita Citraro, Luigi Del Gaudio, Salvatore Striano, Giovambattista De Sarro, Emilio Russo, Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis, Expert Opinion on Pharmacotherapy, 2015, 16, 15, 2355

    CrossRef

  5. 5
    Alan B. Ettinger, Antonia LoPresti, Haichen Yang, Betsy Williams, Sharon Zhou, Randi Fain, Antonio Laurenza, Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel, Epilepsia, 2015, 56, 8
  6. 6
    Gaetano Zaccara, Fabio Giovannelli, Gail S. Bell, Josemir W. Sander, Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective, European Journal of Clinical Pharmacology, 2014, 70, 6, 647

    CrossRef

  7. 7
    Steve S Chung, Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate, Clinical Investigation, 2014, 4, 9, 839

    CrossRef

  8. 8
    Lynn D. Kramer, Andrew Satlin, Gregory L. Krauss, Jacqueline French, Emilio Perucca, Elinor Ben-Menachem, Patrick Kwan, Jerry J. Shih, Antonio Laurenza, Haichen Yang, Jin Zhu, David Squillacote, Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose–response analysis of phase III studies, Epilepsia, 2014, 55, 3
  9. 9
    Ehab S. El Desoky, The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy, Fundamental & Clinical Pharmacology, 2014, 28, 5
  10. 10
    Takahisa Hanada, The discovery and development of perampanel for the treatment of epilepsy, Expert Opinion on Drug Discovery, 2014, 9, 4, 449

    CrossRef

  11. 11
    Gaetano Zaccara, Fabio Giovannelli, Massimo Cincotta, Alfonso Iudice, AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel, Expert Review of Neurotherapeutics, 2013, 13, 6, 647

    CrossRef

  12. 12
    Lan Gao, Li Xia, Fei-Li Zhao, Shu-Chuen Li, Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials, Epilepsy Research, 2013, 103, 1, 31

    CrossRef

  13. 13
    Barry E. Gidal, Jim Ferry, Oneeb Majid, Ziad Hussein, Concentration–effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures, Epilepsia, 2013, 54, 8
  14. You have free access to this content14
    A. Satlin, L. D. Kramer, A. Laurenza, Development of perampanel in epilepsy, Acta Neurologica Scandinavica, 2013, 127,
  15. 15
    Bernhard J. Steinhoff, Elinor Ben-Menachem, Philippe Ryvlin, Simon Shorvon, Lynn Kramer, Andrew Satlin, David Squillacote, Haichen Yang, Jin Zhu, Antonio Laurenza, Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies, Epilepsia, 2013, 54, 8
  16. You have free access to this content16
    F. Kerling, B.S. Kasper, Efficacy of perampanel: a review of clinical trial data, Acta Neurologica Scandinavica, 2013, 127,
  17. 17
    Vladimir Shvarts, Steve Chung, Epilepsy, Antiseizure Therapy, and Sleep Cycle Parameters, Epilepsy Research and Treatment, 2013, 2013, 1

    CrossRef

  18. 18
    Jacqueline A. French, Gregory L. Krauss, Bernhard J. Steinhoff, David Squillacote, Haichen Yang, Dinesh Kumar, Antonio Laurenza, Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305, Epilepsia, 2013, 54, 1
  19. 19
    V. Franco, F. Crema, A. Iudice, G. Zaccara, E. Grillo, Novel treatment options for epilepsy: Focus on perampanel, Pharmacological Research, 2013, 70, 1, 35

    CrossRef

  20. 20
    Dennis Cada, Terri Levien, Danial Baker, Perampanel, Hospital Pharmacy, 2013, 48, 4, 321

    CrossRef

  21. 21
    Ivan Rektor, Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures, Expert Opinion on Pharmacotherapy, 2013, 14, 2, 225

    CrossRef

  22. 22
    Gregory L. Krauss, Emilio Perucca, Elinor Ben-Menachem, Patrick Kwan, Jerry J. Shih, David Squillacote, Haichen Yang, Michelle Gee, Jin Zhu, Antonio Laurenza, Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307, Epilepsia, 2013, 54, 1
  23. 23
    Gregory L. Krauss, Perampanel: A Selective AMPA Antagonist for Treating Seizures, Epilepsy Currents, 2013, 13, 6, 269

    CrossRef

  24. 24
    Vladimir Shvarts, Steve Chung, Perampanel: newly approved, novel antiepileptic medication for partial-onset seizures, Expert Review of Neurotherapeutics, 2013, 13, 2, 131

    CrossRef

  25. 25
    David R. M. Ledingham, Philip N. Patsalos, Perampanel: What is its Place in the Management of Partial Onset Epilepsy?, Neurology and Therapy, 2013, 2, 1-2, 13

    CrossRef

  26. 26
    Meir Bialer, Svein I. Johannessen, René H. Levy, Emilio Perucca, Torbjörn Tomson, H. Steve White, Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI), Epilepsy Research, 2013, 103, 1, 2

    CrossRef

  27. 27
    Ashley E. Feldman, Barry E. Gidal, QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy, Epilepsy & Behavior, 2013, 26, 3, 421

    CrossRef

  28. You have free access to this content28
    J. M. Serratosa, V. Villanueva, F. Kerling, B. S. Kasper, Safety and tolerability of perampanel: a review of clinical trial data, Acta Neurologica Scandinavica, 2013, 127,
  29. 29
    Michele A Faulkner, Rachel A Burke, Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel, Expert Opinion on Drug Safety, 2013, 12, 6, 847

    CrossRef

  30. 30
    Warrington W. Q. Hsu, C. W. Sing, Ying He, Alan J. Worsley, Ian C. K. Wong, Esther W. Chan, Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy, CNS Drugs, 2013, 27, 10, 817

    CrossRef

  31. 31
    G. Zaccara, F. Giovannelli, M. Cincotta, A. Verrotti, E. Grillo, The adverse event profile of perampanel: meta-analysis of randomized controlled trials, European Journal of Neurology, 2013, 20, 8
  32. 32
    Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, J. Robert Merritt, 2013,

    CrossRef

  33. 33
    Shigeki Hibi, Koshi Ueno, Satoshi Nagato, Koki Kawano, Koichi Ito, Yoshihiko Norimine, Osamu Takenaka, Takahisa Hanada, Masahiro Yonaga, Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist, Journal of Medicinal Chemistry, 2012, 55, 23, 10584

    CrossRef

  34. 34
    A Wickenden, B Priest, G Erdemli, Ion channel drug discovery: challenges and future directions, Future Medicinal Chemistry, 2012, 4, 5, 661

    CrossRef

  35. 35
    Thomas Mayer, Neues Antiepileptikum gegen fokale Anfälle?, DNP - Der Neurologe und Psychiater, 2012, 13, 7-8, 28

    CrossRef

  36. 36
    Emilio Russo, Rosaria Gitto, Rita Citraro, Alba Chimirri, Giovambattista De Sarro, New AMPA antagonists in epilepsy, Expert Opinion on Investigational Drugs, 2012, 21, 9, 1371

    CrossRef

  37. 37
    Greg L. Plosker, Perampanel, CNS Drugs, 2012, 26, 12, 1085

    CrossRef

  38. You have free access to this content38
    I. Rektor, G. L. Krauss, M. Bar, V. Biton, J. A. Klapper, N. Vaiciene-Magistris, R. Kuba, D. Squillacote, M. Gee, D. Kumar, Perampanel Study 207: long-term open-label evaluation in patients with epilepsy, Acta Neurologica Scandinavica, 2012, 126, 4
  39. 39
    Joseph I. Sirven, Perampanel: Getting AMPed for AMPA Targets, Epilepsy Currents, 2012, 12, 6, 241

    CrossRef

  40. 40
    Marco Mula, Recent and future antiepileptic drugs and their impact on cognition: what can we expect?, Expert Review of Neurotherapeutics, 2012, 12, 6, 667

    CrossRef

  41. 41
    Pablo M. Casillas-Espinosa, Kim L. Powell, Terence J. O’Brien, Regulators of synaptic transmission: Roles in the pathogenesis and treatment of epilepsy, Epilepsia, 2012, 53,
  42. 42
    Dieter Schmidt, Antiepileptic Drug Development,
  43. 43
    Antonio Laurenza, Jim Ferry, Haichen Yang, Shigeki Hibi, Takahisa Hanada, Andrew Satlin, Case Study 1,
  44. 44
    Edward Faught, Perampanel,
  45. 45
    Nandini C. Patel, Perampanel (Fycompa): AMPA Receptor Antagonist for the Treatment of Seizure,
  46. 46
    Jianyi Huang, Yousheng Xiao, Man Luo, Hongye Luo, Jin Wang, Perampanel add-on for drug-resistant partial epilepsy, The Cochrane Library,
  47. 47
    Shigeki Hibi, Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy,